openPR Logo
Press release

Polycythemia Vera Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Sanofi, Roche, Kartos Therapeutics, AOP Orphan Pharmaceuticals AG

08-10-2023 04:56 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Polycythemia Vera Pipeline Assessment (2023) Covering

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Polycythemia Vera therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Polycythemia Vera Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Polycythemia Vera Therapeutics Market.

The report provides a detailed description of the Polycythemia Vera drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Polycythemia Vera Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Polycythemia Vera Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Polycythemia Vera therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia Vera treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Polycythemia Vera drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Polycythemia Vera treatment market.

Learn More about the Clinical and Commercial Development Activities in the Polycythemia Vera Therapeutics Domain:
https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Polycythemia Vera Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Polycythemia Vera pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Request for Sample PDF to Understand More About the Polycythemia Vera Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Polycythemia Vera Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Polycythemia Vera. Currently, Protagonist Therapeutics is leading the therapeutics market with its Polycythemia Vera drug candidates in the most advanced stage of clinical development.

Polycythemia Vera Companies in the Therapeutics Market Include:
• Protagonist Therapeutics
• Imago BioSciences
• Italfarmaco
• Sanofi
• Roche
• Kartos Therapeutics, Inc.
• AOP Orphan Pharmaceuticals AG
And Many Others

Emerging and Marketed Polycythemia Vera Therapies Covered in the Report Include:
• PTG-300: Protagonist Therapeutics
• Bomedemstat: Imago BioSciences
• Givinostat: Italfarmaco
And Many More

Get an in-depth Assessment of the Emerging Therapies and Polycythemia Vera Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Polycythemia Vera Current Treatment Patterns
4. Polycythemia Vera - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Polycythemia Vera Late-Stage Products (Phase-III)
7. Polycythemia Vera Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Polycythemia Vera Discontinued Products
13. Polycythemia Vera Product Profiles
14. Polycythemia Vera Companies
15. Polycythemia Vera Drugs
16. Dormant and Discontinued Products
17. Polycythemia Vera Unmet Needs
18. Polycythemia Vera Future Perspectives
19. Polycythemia Vera Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market

Dysfunctional Uterine Bleeding Market
https://www.delveinsight.com/report-store/dysfunctional-uterine-bleeding-market

Status Epilepticus Market
https://www.delveinsight.com/report-store/status-epilepticus-market

Brain Hemorrhage Market
https://www.delveinsight.com/report-store/brain-hemorrhage-market

Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market

Ductal Carcinoma in Situ Market
https://www.delveinsight.com/report-store/ductal-carcinoma-in-situ-market

Electroencephelographs (EEG) Pipeline Insight
https://www.delveinsight.com/report-store/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape

Spinal Decompression/Traction Devices Market
https://www.delveinsight.com/report-store/spinal-decompression-traction-devices-market

Bronchopulmonary Dysplasia Market
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market

Drug Hypersensitivity Market
https://www.delveinsight.com/report-store/drug-hypersensitivity-market

Familial Chylomicronemia Syndrome (FCS) Market
https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

Implantable Infusion Pumps Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market

Postmyocardial Infarction Syndrome Market
https://www.delveinsight.com/report-store/postmyocardial-infarction-syndrome-market

Surgery and Radiation Therapy in Brain Cancer Market
https://www.delveinsight.com/report-store/surgery-and-radiation-therapy-in-brain-cancer-market

Acute ischemic stroke (AIS) Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market

Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market

Gene Therapy for Ocular Rare Disease Market
https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-market

Hemophagocytic Lymphohistiocytosis Market
https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market

Staphylococcus Aureus Infection Market
https://www.delveinsight.com/report-store/staphylococcus-aureus-infection-market

Treatment-Resistant Hypertension Market
https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market

Urticaria Or Hives Market
https://www.delveinsight.com/report-store/urticaria-or-hives-market

Acute Heart failure Market
https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market

Bowen's Disease Market
https://www.delveinsight.com/report-store/bowens-disease-market

Contrast-Induced Nephropathy Market
https://www.delveinsight.com/report-store/contrast-induced-nephropathy-market

Delirium Market
https://www.delveinsight.com/report-store/delirium-market

Dry AMD MarketEGFR Inhibitors-Induced Skin Disorders Market
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market

Excessive Daytime Sleepiness (EDS) Market
https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market

Gene and Cell Therapies Targeting CNS Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market

Glioma Market
https://www.delveinsight.com/report-store/glioma-market

Graves Ophthalmopathy Market
https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

H3N2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market

Nontuberculous Mycobacterial (NTM) Infections Market
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market

Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market

Pneumothorax Treatment Devices Market
https://www.delveinsight.com/report-store/pneumothorax-treatment-devices-market

Portal Hypertension Market
https://www.delveinsight.com/report-store/portal-hypertension-market

Decompensated Cirrhosis Market
https://www.delveinsight.com/report-store/decompensated-cirrhosis-market

Follicular Lymphoma Market
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights

Osteochondromas Market
https://www.delveinsight.com/report-store/osteochondromas-market

Hidradenitis Suppurativa Market
https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market

IgG4-Related Disease Market
https://www.delveinsight.com/report-store/igg4-related-disease-market

Lichen Planus Market
https://www.delveinsight.com/report-store/lichen-planus-market

Retinal Vein Occlusion Market
https://www.delveinsight.com/report-store/retinal-vein-occlusion-market

Meniere's Disease Market
https://www.delveinsight.com/report-store/menieres-disease-md-market

Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

Angelman Syndrome Market
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast

Eosinophilic Gastroenteritis (EGE) Market
https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market

Hereditary Transthyretin Amyloidosis (hATTR) Market
https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market

Implantable Infusion Pumps Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market

Post-Operative Cataract Surgery Inflammation Market
https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market

Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Polycythemia Vera Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Sanofi, Roche, Kartos Therapeutics, AOP Orphan Pharmaceuticals AG here

News-ID: 3161839 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Polycythemia

Polycythemia Vera Market Massive Growth opportunity Ahead
Polycythemia Vera Market Outlook 2024-2034: Rising Diagnosis Rates and Advancements in Targeted Therapies to Drive Growth Introduction Polycythemia Vera (PV) is a rare chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, and in some cases, white blood cells and platelets. This leads to increased blood viscosity, higher risk of thrombosis, fatigue, headaches, and splenomegaly. PV is primarily associated with mutations in the JAK2 gene, which has shaped the
Polycythemia Vera Pipeline: 10+ Therapies in Development by Pharma Giants Poised …
The Polycythemia Vera (PV) treatment landscape is undergoing significant evolution, driven by leading biopharmaceutical companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, and Perseus Proteomics. With JAK inhibitors like ruxolitinib already established, the focus has now shifted to next-generation therapeutics targeting disease-modifying mechanisms, cytokine signaling pathways, and novel erythropoiesis regulation. These therapies aim to reduce thrombotic risk, alleviate symptom burden, and delay progression to myelofibrosis. DelveInsight's "Polycythemia Vera - Pipeline Insight,
Polycythemia Clinical Trials, Drugs, Key Companies, Polycythemia Treatment Marke …
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight. Polycythemia Overview: Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029). Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.